Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
Top Page
Alpha Cognition Inc
(NASDAQ:ACOG)
Rating:38Underperform
Price Target:―
Positive Factors
Market Potential
ZUNVEYL is expected to generate significant annual sales based on the long-term care market segment alone, with potential to reach $540M in peak annual sales in the U.S.
Product Launch
The launch metrics for ZUNVEYL are promising, with positive feedback from prescribers and no reported adverse events.
Sales Forecast
Alpha Cognition's sales exceeded expectations, leading to an increase in sales forecasts for the upcoming years.
Negative Factors
Market Risks
Risks include inability to launch ZUNVEYL in an optimized or timely manner and slower-than-expected market uptake due to pricing pressures or higher-than-anticipated competition.
Pricing Pressures
Slower-than-expected market uptake of ZUNVEYL might occur due to pricing pressures.
Alpha Cognition Inc (ACOG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$143.14M
Dividend YieldN/A
Average Volume (3M)146.46K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth43.76%
CountryUS
Employees5
SectorHealthcare
Sector Strength46
IndustryFinancial - Conglomerates
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,019,787
10 Day Avg. Volume67,425
30 Day Avg. Volume146,463
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.00Price Target Upside375.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Alpha Cognition Inc Business Overview & Revenue Model
Company DescriptionAlpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyAlpha Cognition Inc generates revenue through the development and commercialization of its therapeutic products. The company primarily makes money by advancing its drug candidates through clinical trials and eventually bringing them to market, either independently or through strategic partnerships and collaborations with larger pharmaceutical companies. These partnerships may involve licensing agreements, where Alpha Cognition receives upfront payments, milestone payments based on the achievement of certain development and regulatory goals, and royalties on future sales of the approved products. Additionally, the company may also receive funding from grants or research collaborations aimed at fostering innovation in the neurodegenerative disease space. The successful commercialization of its drug candidates is crucial to the company's revenue generation and growth.
Alpha Cognition Inc Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: -38.63%|
Next Earnings Date:Aug 20, 2025
Earnings Call Sentiment Positive
The earnings call conveyed a largely positive sentiment, highlighting a successful launch of ZUNVEYL, strong financial position with a debt-free balance sheet, and promising partnerships and patent developments. The positive aspects were slightly tempered by the ongoing operating loss and lack of revenue guidance, but these did not overshadow the overall positive outlook.Q1-2025 Updates
Positive Updates
Commercial Launch of ZUNVEYL
The company successfully launched ZUNVEYL, a treatment for mild to moderate Alzheimer's disease, and reported $1 million in net sales just four weeks into the launch.
Partnership with CMS Pharmaceuticals
Alpha Cognition made significant progress with CMS Pharmaceuticals for ZUNVEYL distribution in China and other Asian territories, expecting regulatory submission in China by Q4 2025.
Financial Strength and Flexibility
The company ended the first quarter with approximately $45.5 million in unrestricted cash and cash equivalents, and successfully retired a $900,000 debt obligation, resulting in a debt-free balance sheet.
Patent Approvals
Received a new U.S. patent for pH-dependent release of benzgalantamine, providing additional protection through 2044, and submitted for patent extension on an early method of use patent.
Positive Market Feedback
Early market feedback for ZUNVEYL has been positive, with high prescriptions and minimal adverse events reported, indicating a strong start for the product.
Negative Updates
Operating Loss
The company reported an operating loss of $3.7 million for Q1 2025, though this was an improvement from $4.4 million in the same period in 2024.
No Revenue Guidance
The company did not provide revenue guidance for the full year 2025, which may create uncertainty about future financial performance.
Company Guidance
During the Alpha Cognition earnings call, guidance for the fiscal year 2025 was provided with several key metrics highlighted. The company, led by Interim CFO Henry Du, reported a net loss reduction to $2 million, or $0.13 per share, compared to a $5 million loss, or $0.87 per share, in Q1 2024. Initial net product revenues from ZUNVEYL reached $347,000, with recognized licensing revenue of $2.6 million. Alpha Cognition maintained a strong balance sheet with $45.5 million in unrestricted cash and cash equivalents, and retired a $900,000 debt obligation. While revenue guidance was not provided, the company reiterated its full-year expense guidance in the range of $38 million to $42 million. The commercial launch of ZUNVEYL has shown promising early results, with approximately 500 bottles ordered and $1 million in net sales through April 30, despite launching without payer contracts. The company plans modest single-digit increases in headcount and anticipates moving to a positive cash flow position by year three, contingent on successful execution of its strategic plan.Alpha Cognition Inc Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||
| Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|
| Income Statement | Total Revenue | |
| ― | ― | ― | Gross Profit |
| ― | ― | ― | EBIT |
| -9.62M | -13.47M | -11.57M | EBITDA |
| -13.62M | -14.91M | -18.93M | Net Income Common Stockholders |
| -13.77M | -15.17M | -19.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
| ― | ― | ― | Total Assets |
| 2.45M | 2.95M | 12.88M | Total Debt |
| 1.22M | 1.21M | 1.08M | Net Debt |
| -183.79K | -872.23K | -10.23M | Total Liabilities |
| 7.16M | 4.27M | 3.85M | Stockholders Equity |
| ― | ― | ― |
| Cash Flow | Free Cash Flow | |
| ― | ― | -9.88M | Operating Cash Flow |
| -8.73M | -9.24M | -9.88M | Investing Cash Flow |
| ― | ― | ― | Financing Cash Flow |
| ― | ― | ― |
Alpha Cognition Inc Technical Analysis
Positive
4.21
Price Trends
7.43
Positive
6.54
Positive
7.19
Positive
Market Momentum
0.40
Positive
54.44
Neutral
32.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACOG, the sentiment is Positive. The current price of 4.21 is below the 20-day moving average (MA) of 9.29, below the 50-day MA of 7.43, and below the 200-day MA of 7.19, indicating a neutral trend. The MACD of 0.40 indicates Positive momentum. The RSI at 54.44 is Neutral, neither overbought nor oversold. The STOCH value of 32.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACOG.
Alpha Cognition Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $96.57M | 13.93 | 17.69% | ― | 16.51% | ― | |
53 Neutral | $5.22B | 3.33 | -44.36% | 7.55% | 16.78% | -0.12% | |
47 Neutral | $55.55M | ― | -116.63% | ― | -100.00% | 24.59% | |
38 Underperform | $143.14M | ― | -56.79% | ― | ― | 43.76% | |
37 Underperform | $116.19M | ― | -154.55% | ― | ― | 19.70% | |
37 Underperform | $78.57M | ― | -63.22% | ― | -100.00% | -26.44% | |
33 Underperform | $132.49M | 37.76 | 4.14% | ― | ― | 33.97% |
* Healthcare Sector Average
Performance Comparison
ACOG
Alpha Cognition Inc
9.16
-4.09
-30.87%
ACHV
Achieve Life Sciences
3.35
-1.38
-29.18%
WHWK
Whitehawk Therapeutics
2.09
0.34
19.43%
BDTX
Black Diamond Therapeutics
2.33
-2.55
-52.25%
PLRX
Pliant Therapeutics
1.28
-10.07
-88.72%
SNTI
Senti Biosciences
2.13
-0.39
-15.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.